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Experimental data suggest that BRCA1 related breast
cancer may have increased sensitivity to platinum-based
chemotherapy, but clinical data are limited. Herein we
summarize our clinical observations on treatment with
cicplatinum of BRCA1 mutation carriers affected with
breast cancer.
A) Neoadjuvant therapy
Eighty women with breast cancer and a BRCA1 mutation
with stage I, II, and III breast cancer between December
2006 and February 2012 were entered into this study.
Patients were treated with cisplatin 75 mg/m2 intrave-
nously every three weeks for four cycles. After chemother-
apy, patients underwent surgery and were assessed for
pathologic response in both the breast and axillary lymph
nodes. Pathologic complete response was observed in 63%
of women. Conclusions: Platinum-based chemotherapy is
effective in a high proportion of patients with BRCA1-
associated breast cancers. Clinical trials are warranted to
determine the optimum treatment for this subgroup of
breast cancer patients.
B) Treatment of metastatic breast cancer
Between July 2007 and January 2009, in a phase II, open-
label study, 20 patients with metastatic breast cancer who
carried a mutation in BRCA1 were treated with cisplatin
75 mg/m2 intravenously every 3 weeks as part of a 21-
day cycle for 6 cycles. Restaging studies to assess
response were performed after cycles 2 and 6, and every
three months thereafter. Overall response rate was 80%;
nine patients experienced a complete clinical response
(45%) and seven experienced a partial response (35%).
Overall survival was 80% at one year, 60% at two years
and 25% at three years. Four of the 20 patients are alive
four years after initiating treatment. The median time to
progression was 12 months. The median survival from
the start of cisplatinum treatment was 30 months. Cispla-
tin-related adverse events, including nausea (50%), ane-
mia (5%) and neutropenia (35%) were mostly mild to
moderate in severity.
Conclusions
This phase II study demonstrates that cisplatin che-
motherapy has high activity in women with a BRCA1
mutation and metastatic breast cancer and is generally
well tolerated.
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